Pfizer's latest cutbacks will provide a new outsourcing opportunity
for contract manufacturing organisations (CMOs) in low-cost
destinations as the drug giant announces plans to double its amount
of drug production outsourcing.
Charles River Laboratories confirmed it is persevering in its
intention to focus on its preclinical and Phase I businesses while
abandoning its late stage development services, during a conference
earlier this month.
Covance was nothing but optimistic about the future of contract
research organisations (CROs) during a JPMorgan healthcare
conference held last week, despite a slowdown in R&D spending
over the past year.
Singapore is planning to double the number of clinical trials it
runs over the next five year, particularly in early phase research,
as it looks to hold its ground amidst industry explosion in the
The booming pharmaceutical contract research market sees a new
player enter the arena as analytical lab Eno River Labs separates
into two independent divisions to create a new business that will
provide analytical and formulation...
Caliper Life Sciences is making the most of its recent acquisitions
by launching a new drug discovery and development services business
- created from the integration of two companies it recently bought
- in a bid to offer a "in...